miR-515-5p controls cancer cell migration through MARK4 regulation

Olivier E. Pardo*#1, Leandro Castellano*1, Catriona E. Munro*1, Yili Hu3, Francesco Mauri1, Jonathan Krell1, Romain Lara1, Filipa G. Pinho1, Thameenah Choudhury 1, Adam E Frampton1, Loredana Pellegrino1, Dmitry Pshezhetskiy1, Yulan Wang3, Jonathan Waxman1, Michael J. Seckl#1,2, Justin Stebbing1,2#

1Division of Cancer, Dept. of Surgery & Cancer, Imperial Centre for Translational and Experimental Medicine (ICTEM), Imperial College, Hammersmith Hospital campus, Du Cane Road, London, W12 0NN, UK.

2Dept. of Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, 1st Floor, E Wing, Fulham Palace Road, London, W6 8RF, UK.

3Key Laboratory of Magnetic Resonance in Biological Systems, Wuhan Center for Magnetic Resonance, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, 430071, PR China.

*contributed equally to the work.

#To whom correspondence should be addressed:
Keywords: Breast cancer, Lung cancer, Cell migration, Microtubule affinity-regulating kinase 4, microRNAs, miR-515-5p

Abstract: 147 words; Character count (text): ~40,000

Total number of figures and tables: 7
Grant support: We would like to thank Builder Depot Ltd and The Harold and Daphne Cooper Charitable Trust, the Fundação para a Ciência e Tecnologia, Portugal (F.G. Pinho; SFRH/BD/68267/2010) and the Medical Research Council with Johnson & Johnson (CE. Munro-MRC CASE G1000390 and JK) for their support. Also OP was supported by EU FP7 funding under the LungTarget consortium. In addition, this study was supported by the Imperial Experimental Cancer Medicine Centre (ECMC), the NIHR Imperial Biomedical Research Centre (BRC), Cancer Treatment and Research Trust (CTRT) and the Association for International Cancer Research (AICR). For additional support, we acknowledge Action Against Cancer, the NIHR (JS), Cancer Research UK (JS and RL), the Association for International Cancer (LC), the Breast Cancer Campaign (LP) and the Roter family foundation. This paper is written in memory of Leslie Aaronson.

Acknowledgements: We thank Harikrishna Nakshatri for the MDA-MB-231 cells derived from metastatic loci in nude mice.

Disclosure of Potential Conflicts of Interest: No potential conflicts of interest.
Authors' Contributions

**Conception and design:** Justin Stebbing, Catriona E. Munro, Filipa G. Pinho, Leandro Castellano, Michael Seckl

**Development of methodology:** Catriona E. Munro, Filipa G. Pinho, John Krell, Olivier Pardo, Romain Lara, Loredana Pellegrino

**Acquisition of data:** Olivier Pardo, Leandro Castellano, Catriona E. Munro, Filipa G. Pinho

**Analysis and interpretation of data:** Olivier Pardo, Catriona E. Munro, Filipa G. Pinho, Leandro Castellano, Justin Stebbing

**Writing, review, and/or revision of the manuscript:** Olivier Pardo, Catriona E. Munro, Filipa G. Pinho, Justin Stebbing, Leandro Castellano, Jonathan Waxman, Michael Seckl

**Administrative, technical, or material support:** Justin Stebbing, Michael Seckl, Jonathan Waxman

**Study supervision:** Olivier Pardo, Justin Stebbing, Leandro Castellano, Michael Seckl, Jonathan Waxman, Dmitry Pshezhetskiy
ABSTRACT

Here we show that miR-515-5p inhibits cancer cell migration and metastasis. RNA-seq analyses of both estrogen receptor-positive and negative breast cancer cells over-expressing miR-515-5p reveals down-regulation of NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 mRNAs. We demonstrate that miR-515-5p inhibits MARK4 directly 3'UTR interaction and that MARK4 knockdown mimics the effect of miR-515-5p on breast and lung cancer cell migration. MARK4 over-expression rescues the inhibitory effects of miR-515-5p, suggesting miR-515-5p mediates this process through MARK4 down-regulation. Furthermore, miR-515-5p expression is reduced in metastases compared to primary tumours derived from both in vivo xenografts and samples from patients with breast cancer. Conversely, miR-515-5p overexpression prevents tumour cell dissemination in a mouse metastatic model. Moreover, high miR-515-5p and low MARK4 expression correlate with increased breast and lung cancer patients’ survival, respectively. Taken together, these data demonstrate the importance of miR-515-5p/MARK4 regulation in cell migration and metastasis across two common cancers.
INTRODUCTION

Initially termed MARKL1 (microtubule affinity-regulating kinase-like 1), MARK4 was identified by a cDNA microarray approach to be down-regulated following a decrease in TCF/LEF1 (transcription complex, T-cell factor/lymphoid enhancer-binding factor) activity in hepatocellular carcinoma cell lines. To date MARK4 expression has been found to be increased in hepatocellular carcinomas and gliomas, suggesting a role for MARK4 in cancer development [1, 2]. Using a tandem affinity purification approach, MARK4 was found to interact with a number of proteins linked to the regulation of cell motility, namely 14-3-3 proteins, ARHGEF2 (GEF-H1) - a microtubule-associated exchange factor for Rho GTPases and Phosphatase 2A (PP2A); and was previously shown to dephosphorylate TAU and other MAPs controlling their microtubule binding affinity [3, 4]. The identification of these binding partners and MARK4’s interaction with three forms of tubulin (α-, β-, γ-tubulin), myosin and actin suggest a clear role for MARK4 in control of the cytoskeleton [5, 6]. However, nothing is known about the control of MARCK4 expression by for example microRNAs.

MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression through binding to the 3’ UTR of their mRNA targets. In 2009, it was shown that more than 50% of known miRNA target genes are located in cancer-associated genomic regions (CAGRs), regions in the genome that are frequently altered in various cancers [7]. Therefore, unsurprisingly, the expression of miRNAs are often altered among different cancer sub-types and assessment of the expression of certain miRNAs has allowed for the accurate differentiation between benign and malignant tissues [8]. More recently, systemic injection of synthetic tumor suppressor miRNAs has been demonstrated to successfully prevent the growth of metastases in animal models with cancer metastasis [9]. This evidence suggests that miRNAs-based therapies could
be used to treat metastatic disease or to prevent the formation of metastasis in early-stage disease.

miR-515-5p was initially described to be a placenta-specific miRNA involved in fetal growth [10]. However, recently, we identified its role as a tumor suppressor in breast cancer [11]. We demonstrated that miR-515-5p transcription was directly down-regulated by the estrogen receptor and that miR-515-5p inhibited breast cell proliferation by inducing apoptosis [11]. During this work a change in MCF-7 and MDA-MB-231 cell morphology was also observed, a finding that we investigate further here.

Indeed, we show that miR-515-5p over-expression increases microtubule area not only in breast cancer but also in non-small cell lung cancer (NSCLC) cells and that this correlates with decreased cell migration. We performed an RNA-seq following the over-expression of miR-515-5p in MCF7 and MDA-MB-231 cells, which revealed the down-regulation of five transcripts linked to cell migration: NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 [6, 12-15]. These 4 transcripts were also down-regulated in A549 and H1299 NSCLC cells in response to miR-515-5p overexpression and luciferase reporter constructs indicating that miR-515-5p directly regulated NRAS, PIK3C2B and MARK4 expression in multiple cancer cells. As the strongest down-regulation of expression by miR-515-5p was seen with MARK4 in both MCF7 and MDA-MB-231 and that this gene had previously been reported to modulate NSCLC cell motility [16], we decided to focus our study on investigating the direct regulation of MARK4 expression by miR-515-5p. We showed that MARK4 silencing reproduces the morphological and cell migration changes observed following miR-515-5p over-expression in both breast and NSCLC cells, demonstrating this to be a consistent phenomenon across two separate tumor types. Conversely, transfection of exogenous MARK4 into miR-515-5p over-expressing cells rescued the observed decrease in cell migration, suggesting that MARK4 down-regulation is a crucial mechanism through which miR-515-5p reduces cell motility. By analysing miR-515-5p expression in tumor samples derived from breast cancer patients,
we observed its expression to be inversely correlated with metastasis, while expression of miR-515-5p mimics in A549 NSCLC cells prevented \textit{in vivo} tumor cell dissemination in a metastatic mouse model. In agreement with metastasis being a poorer prognosis factor for cancer patients, decreased miR-515-5p or increased MARK4 expression were indicative of poorer survival in both metastatic breast and lung cancer. In short, our data demonstrate that miR-515-5p dramatically inhibits cell migration by directly down-regulating MARK4 expression in two different cancer types and suggests a role for miR-515-5p and MARK4 as potential biomarkers in metastatic disease and as possible therapeutic targets.
RESULTS

miR-515-5p changes cell morphology and inhibits cell migration in breast cancer

We initially over-expressed miR-515-5p in breast (MCF7 and MDA-MD-231) and lung (A549 and H1299) cell lines (Appendix Figure S1A) and stained for tubulin to assess cell morphology. We observed an increase in cell area and loss of cell polarity (Figure 1A). The loss of cell polarity was confirmed quantitatively by comparing the cell circularity factor of individual cells in 10 fields of view between control and miR-515-5p over-expressing conditions for the four cell lines (Appendix Figure S2). Overexpression of miR-515-5p significantly increased the circularity factor towards a value of 1, indication loss of cell elongation.

As cell cytoskeleton dynamics and cell polarity are crucial for cell motility, we wished to investigate whether this change in morphology affected cancer cell migration. We analyzed the effect of miR-515-5p over-expression in MDA-MB-231, A549 and H1299 on random and directional migration by conducting random and boyden chamber directional cell migration assays. We observed a sharp decrease in random and directional cell migration in miR-515-5p-transfected cells as compared to their miRVANA non-targeting controls (NC) (Figures 1B-C). This however was not the result of overexpression of this miRNA inducing apoptotic cell death as shown in Appendix Figure S1B for A549 and H2199 cells and previously published by us for MDA-MB-231 [11]. Hence, miR-515-5p overexpression is able to directly suppress cell migration in these cell lines possibly as a consequence of the observed changes to the cell cytoskeleton.

miR 515-5p directly regulates NRAS, MARK4 and PIK3C2B expression
To identify which miR-515-5p targets were responsible for its effect on cancer cell migration, we performed an RNA-seq analysis of MCF7 and MDA-MB-231 cells over-expressing miR-515-5p. Interestingly, we found 5 down-regulated transcripts which were predicted to interact with miR-515-5p and have also been implicated in cell migration: NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 (Figure 2A, Table EV1) [6, 12-15]. To validate the RNA-seq results, we performed validatory qPCRs for the levels of these five transcripts in MCF7 and MDA-MB-231 cells upon the over-expression of miR-515-5p (Figures 2B and 2C) and miR-515-5p sponge vectors (Appendix Figure Ss 3A-B), which reduce the levels of miR-515-5p by directly interacting with its mature form. miR-515-5p sponge vectors induced an increase in the levels of the 5 transcripts in MCF7 but not within MDA-MB-231 cells (Appendix Figure Ss 3A-B). This is likely to be because miR-515-5p expression is much lower in MDA-MB-231 than in MCF7 (Appendix Figure S4), Conversely, we observed a significant down-regulation of the expression of all five transcripts in the miR-515-5p-transfected MCF7 cells but only a decrease in N-RAS, PI3KC2B and MARK4 mRNA levels in miR-515-5p-transfected MDA-MB-231 (Figures 2B and 2C). Interestingly, miR-515-5p dramatically decreased MARK4 mRNA expression (>95%) in both MCF7 and MDA-MB-231 cells (P < 0.001; Figure 2B and 2C). Levels of these five transcripts were also decreased in NSCLC cells (A549 and H1299) upon over-expression of miR-515-5p (although not significantly for CDC42BPA in A549 cells), underlying a common molecular function for this miRNA across tumor types (Figure 2D).

We then wished to assess whether the transcripts for N-RAS, MARK4 and PI3KC2B could be directly regulated by the binding of miR-515-5p to their 3'UTRs. We used a reporter system where luciferase expression was under the control of the 3'UTRs of our proposed targets. We showed that miR-515-5p negatively regulated the levels of luciferase reporter expression in both MCF7 and MDA231 cells by directly interacting with the 3'UTR regions of N-RAS, MARK4 and PI3KC2B (P < 0.001; Figures 2D and
miR-515-5p and cell migration Pardo et al

This demonstrated that the mRNAs for these three proteins were true direct targets of miR-515-5p. The specificity of the binding of miR-515-5p to the 3’UTR regions of MARK4 was demonstrated through mutating both the sites predicted by TargetScan in the seed sequence. Indeed, mutation of both sites in the 3’UTR prevented miR-515-5p from inhibiting luciferase expression from our reporter vector (Appendix Figure S5).

Silencing of MARK4 mimics the effect of miR-515-5p on both random and directional migration

As MARK4 was so predominantly down-regulated by miR-515-5p in breast cancer cells (Figure 2B and 2C), we questioned whether silencing MARK4 would mimic the effect of miR-515-5p on cell morphology and in cell migration assays. As MCF7 cells are known to display poor motility, we did not analyze the effect of either miR-515-5p or MARK4 silencing on MCF7 cell migration [20]. Hence we limited our primary analysis to MDA-MB-231, A549 and H1299 cell lines. Transfection of these cell lines with MARK4-targeting siRNAs led to an increase in the cell area and clustering as can be observed following tubulin staining (Figure 3A). The change in cell area (quantified in Figure 3A-right panel) was accompanied by a loss of cell polarity reminiscent of that observed for miR-515-5p transfection (Figure 1A). We therefore proceeded to study possible associated changes in cell motility. Our previously published cell migration screen had revealed that silencing of MARK4 reduced migration in A549 cells [16], so we used this cell line as an internal control in these assays. Random migration (RM) and boyden chamber directional migration (DM) assays showed that MARK4 knockdown inhibited cell migration by 48-61%, 55-58% and 54-56% (RM-DM) in MDA-MB-231, A549 and H1299 cell migration, respectively (Figures 3B-C). To further validate the role of MARK4 in the migration of breast cancer cells, we performed random migration experiments in migratory MDA-157 breast cancer cells and found that MARK4 silencing significantly reduced their motility (Appendix Figure S6B). A similar effect was obtained in these cells upon overexpression of miR-515-5p (Appendix Figure S6B) and was
accompanied by changes in cell morphology comparable to that observed in MDA-MB-231, A549 and H1299 cells (Appendix Figure S6C). Taken together, these data suggest that MARK4 down-regulation might be the major cause for the decrease in cell migration observed upon miR-515-5p over-expression.

**miR-515-5p inhibits cell migration through MARK4 down-regulation**

To clarify the importance of MARK4 in the cell migration inhibition by miR-515-5p, we transfected MDA-MB-231, A549 and H1299 cells with miR-515-5p and, after 24 h, we over-expressed MARK4 in the transfected-cell lines (Appendix Figure S7A). We then analyzed whether MARK4 over-expression rescued the effect of miR-515-5p on the random and directional migration of these cell lines (Figures 4 A-B). There was no significant difference between the distance travelled by MDA-MB-231, A549 and H1299 cells co-over-expressing miR-515-5p and MARK4 and that of cell lines co-transfected with miR NC and empty-vector control plasmid (EV) in the random migration assays (Figure 4A and Appendix Figure S7B). Similarly, in the directional assay, the expression of MARK4 rescued the decrease in MDA-MB-231, A549 and H1299 cell migration, although this was more prominent for the lung cancer cell lines (Figure 4B and Appendix Figure S7C).

**MARK4 silencing triggers cell cycle arrest**

In addition to the changes in cell motility, regulation of microtubule dynamics would also be expected to have significant effects on cell division. We therefore compared the cell cycle distribution between control-transfected A549 cells and cells silenced for MARK4. This analysis revealed that MARK4-downregulated cells accumulated in the G1 phase of the cell cycle while showing a decrease in DNA synthesis (Appendix Figure S8A). This was accompanied by an increase in the levels of p53 as well as its transcriptional target, p21, in MARK4-silenced cells, suggesting that downregulating this
kinase induces cell cycle arrest (Appendix Figure S8B). To analyse the speed of microtubule growth a plasmid encoding GFP tagged End Binding Protein 3 (EB3) was transfected into A549 cells. This protein binds to the growing end of the microtubules (MT) and by imaging the movement of the GFP comets produced as the microtubule grows we were able to quantify the speed of growth and compare this growth rate between cells silenced for MARK4 or transfected with a non-targeting control siRNA. Representative images of the comets for the two conditions can be seen in Appendix Figure S9A. When quantified using Image J and the wrMTrck plugin, the comet speed was found to be significantly higher in cells silenced for MARK4 suggesting an increase in the rate of tubulin polymerisation (Appendix Figure S9B).

**MARK4 expression levels increase during tumorigenesis and are inversely correlated to patient survival**

To assess the clinical relevance of our findings, we first evaluated the potential of MARK4 as prognostic biomarkers in metastatic breast and lung cancer patients (Figure 5).

We analyzed the overall survival (months) of a cohort of patients with metastatic lung or breast cancer and correlated this with the levels of MARK4 mRNA present in their tumors. High levels of MARK4 mRNA correlated with a lower overall survival in ER-negative metastatic breast and lung cancer patients, although this only reached statistical significance in the latter (Figures 5A-B). Quantitative PCR analysis of a lung cancer cDNA array revealed that MARK4 mRNA levels are increased in >50% of tumors as compared to normal lung tissues (Figures 5C). In agreement with this, MARK4 protein was detectable in 37% of lung cancer samples while it remained undetected in normal lung tissue (Figures 5D). When subtypes of lung cancer were separated, MARK4 expression was especially prevalent in adenocarcinoma samples with 53% of cases for this tumor type showing positive MARK4 staining (Figures 5E). In addition, comparison of metastatic and primary lesions form the same patients revealed that MARK4
expression was increased in secondary as compared to primary tumors in 41% of cases (Figure 5F). Hence, these data suggest that MARK4 expression increases during tumorigenesis, impacting negatively on patients’ survival.

Taken together, MARK4 and/or miR-515-5p expression levels may be relevant prognosis markers in both breast and lung cancer.

miR-515-5p expression is inversely correlated with metastasis in breast and lung cancer mouse models

In contrast to MARK4, miR-515-5p expression was positively correlated with overall survival in patients with metastatic breast or lung cancer (Figures 6A-D and Appendix Figure Ss 10A-B). Moreover, in Luminal B breast cancer and in normal breast epithelial cells, miR-515-5p levels were significantly inversely correlated with MARK4 expression and a similar trend existed in the case of luminal A and basal breast cancer (Appendix Figure S11). Because the advent of metastatic disease is one of the main factors that negatively impact on patients’ survival, we proceeded to measure miR-515-5p levels in paired primary and metastatic breast cancer patient samples. This demonstrated a lower mean expression of miR-515-5p in lymph-node metastases compared to their corresponding primary tumors (Figures 6E), either by comparing the absolute values (Figure 6E) or the paired values for each patient (Appendix Figure S12).

To evaluate whether changes to the expression of miR-515-5p directly modulated the metastatic potential of breast and lung cancer cells, we performed two animal experiments. MDA-MB-231 cells have previously been used to induce metastatic lesions in nude mice following inoculation into their mammary fat pads [22]. Using samples from both primary and metastatic lesions obtained in these animals, we showed that miR-515-5p levels were down-regulated in all metastatic lesions regardless of site (lung, bone, brain or adrenal glands) as compared to the corresponding primary tumor (Figure 6F-left panel). This was accompanied by a corresponding increase in MARK4 mRNA levels
at the metastatic sites (Figure 6F-right panel). Interestingly, these changes did not necessarily extend to other miR-515-5p targets, as NRAS expression levels did not vary significantly between primary and metastatic lesions (Appendix Figure S13A) and PI3KC2B expression was only significantly up-regulated in the metastatic cells isolated from brain and adrenal glands (Appendix Figure S13B). Hence, confirming the results of the rescue experiments, these data suggest that MARK4 may be the essential target regulating metastasis downstream of miR-515-5p (Figures 4 A-B). While the preceding results suggested that decreased miR-515-5p expression was associated with the onset of metastasis, they did not demonstrate this change to be a causal phenomenon. Therefore, we wished to examine whether directly changing levels of this miRNA could modulate tumor cells colonization in vivo. A549 cells stably expressing a luciferase reporter gene were transfected with or without miR-515-5p and the cells injected 72 hours later into SCID mice through the tail vein. The animals were then monitored by whole-animal imaging following the administration of luciferin at 4 days and 4 weeks following the injection (Figures 6G-left panel). The bioluminescent signal was then quantified and plotted to show the extent of the metastatic burden (Figures 6G-right panel). This analysis revealed that while cells transfected with a non-targeting miRNA mimic (miR-NC) efficiently colonized the mice, miR-515-5p-transfected cells failed to establish tumors in the injected animals (Figures 6G). Hence, changes in miR-515-5p levels alone are sufficient to modulate the metastatic potential of cancer cells.

**MARK4 silencing prevents metastatic lung colonisation of A549 cells**

We next tested whether MARK4 silencing alone could reproduce the effects of miR-515-5p expression on the metastatic behaviour of A549 cells. A549-Luc cells were transfected with MARK4 siRNAs or a non-targeting sequence and injected 48 h later into Scid mice through the tail vein. Four weeks later, the mice were sacrificed and their lungs extracted and fixed prior to immunohistochemical staining for Luciferase expression. As an internal positive control, we performed the same experiments using cells
overexpressing miR-515-5p or a corresponding non-targeting sequence. Figure 7A shows that, 4 weeks following tail-vein injection, cells transfected with non-targeting siRNA had colonised the lungs of the animals as revealed by the presence of luciferase-positive cells either as single cells (Figure 7A-upper panels) or as tight tumours (Figure 7A-lower panels). Quantification of the percentage of area of the fields of view covered by luciferase-positive cells revealed that MARK4 silencing, just as miR-515-5p overexpression, impaired lung colonisation by A549 cells (Figure 7B). These data further confirm that MARK4, as a downstream target of miR-515-5p, controls the invasive potential of cancer cells.
Having previously demonstrated the role of miR-515-5p as an ER-positive breast cancer tumor suppressor [11], here we show that miR-515-5p inhibits cell migration via its targeting of MARK4. Initially, we investigated the role of miR-515-5p in cell migration because we observed rearrangement of the tubulin cytoskeleton in MCF7 and MDA-MB-231 cells that over-expressed miR-515-5p (Figure 1A). We previously demonstrated that ERα suppresses miR-515-5p expression by direct interaction with its promoter, indicating a link between this miRNA and oestrogen signalling [11]. Interestingly, the expression of miR-515-5p is lower in MCF7 epithelial-like cells than in MDA-MB-231 which are more mesenchymal-like. This suggests that ERα is not the only transcription factor regulating miR-515-5p expression, but additional regulators modulate its levels in association with the mesenchymal phenotype. Both MCF7 and MDA-MB-231 cells appeared enlarged with a loss of polarity that is often associated with non-migratory cells. This change did not correlate with the onset of cell death downstream of this miRNA [11] indicating that the effects of miR-515-5p on cell morphology may be caused by distinct targets and, consequently, through different signalling pathways. Additionally, because MDA-MB-231 is an ER-negative breast cancer cell line, we propose that the estrogen receptor α is not involved in these effects. Moreover, miR-515-5p caused similar cytoskeletal changes in non-small cell lung cancer (NSCLC) cells, highlighting a common function of this miRNA across tumor types.

As altered cytoskeletal dynamics and cell polarity are known to influence cell motility, we investigated the effect of miR-515-5p on cell migration. Consistent with the morphological changes (Figure 1A and Appendix Figure S2 and 6C), miR-515-5p inhibited both random and directional cell migration in both breast and lung cancer cell lines (Figures 1B-C and Appendix Figure S6B). In order to ascertain the mechanism
through which miR-515-5p altered cell morphology and migration and identify its gene targets, we performed an RNA-seq analysis using RNA obtained from miR-515-5p-transfected MCF7 and MDA-MB-231 cells. We identified 5 transcripts down-regulated upon miR-515-5p over-expression: NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 (Figure 2A) and these were validated by qPCR (Figure 2B-C). These transcripts have been described as being involved in cell migration and are predicted by TargetScan to be directly targeted by miR-515-5p [6, 12-15]. Furthermore, we validated this using luciferase report assays that demonstrated that miR-515-5p interacts directly with the 3'UTR of NRAS, PIK3C2B and MARK4 (Figures 2E-F) and showed the same targets to be down-regulated by miR-515-5p in NSCLC cells (Figure 2D). We focussed on investigating whether MARK4 down-regulation mediated the migratory effects of miR-515-5p because this target was most dramatically decreased by miR-515-5p over-expression in breast cancer (Figures 2B and 2C) and had previously been involved in microtubule dynamics[6]. TargetScan predicted two different sites of miR-515-5p interaction in MARK4 3'UTR and using site directed mutagenesis coupled with luciferase assay and over-expression of miR-515-5p mimic we demonstrated that miR-515-5p post-trascriptionally repress MARK4 expression interacting with both sites (Appendix Figure S5). Interestingly, MARKs phosphorylate Microtubule Associated Proteins (MAPs) on their microtubule binding domain, disrupting their binding to tubulin and the dynamics of microtubules. In agreement with our hypothesis, silencing MARK4 mimics the changes in the tubulin cytoskeleton and inhibition of cell migration obtained downstream of miR-515-5p overexpression in all cell lines tested (Figures 3A-C and Appendix Figure S6C). This correlated with an increase in the rate of microtubule polymerisation downstream of MARK4 silencing (Appendix Figure S9). MARKs activity has been shown to be regulated by a number of different processes including phosphorylation, ubiquitination and interaction with inhibitory proteins [23]. However to our knowledge, this is the first report of the regulation of a MARK family member by a micro-RNA.
To test our hypothesis that MARK4 down-regulation was the mechanism through which miR-515-5p affected breast cancer cell migration, we tested whether over-expressing MARK4 in miR-515-5p–transfected cells could rescue the reduced cell motility. In agreement with our hypothesis, MARK4 over-expression rescued the effect of miR-515 on random cell migration (Figure 4A-B). However, increased MARK4 expression did not completely rescue the effect of miR-515-5p over-expression on directional migration in two out of the three cell lines tested (Figures 5A-B). This may be due to the additional factors regulating directional cell migration, such as sensing of growth factor gradient and cell deformability that may require input from additional miR-515-5p targets. However, since rescue of both types of migration was almost total (80-100%), our data suggest that MARK4 down-regulation is probably the main mediator of cell migration regulation by miR-515-5p.

We wished to assess whether these in vitro finding showed any clinical relevance and quantified miR-515-5p in tissues from breast cancer patients. We found that miR-515-5p expression was significantly reduced in lymph nodes metastasis compared to primary tumors derived from the same breast cancer patients (Figure 6E and Appendix Figure S12). Moreover, we found that low miR-515-5p expression correlated with poorer survival in breast and lung cancer (Figure 6A-D). The opposite correlation existed for MARK4 expression, with high expression of this kinase correlating with poorer survival in these two cancer types (Figure 5A-B). Moreover, MARK4 was clearly up-regulated during lung tumorigenesis and further increased in metastatic lesions in over 40% of cases (Figure 5C-F). MARK4 has previously been shown to be up-regulated in glioma and hepatocellular carcinomas [1, 2] and associated with Wnt-induced tumorigenesis in the prostate [24]. Nevertheless, this is the first report of its overexpression during lung tumorigenesis and of its particular association with the metastatic process. This link between changes in MARK4 expression and clinical metastatic disease was supported by our experimental data using animal models. Indeed, we quantified MARK4 levels in
metastatic lesions obtained following the inoculation of MDA-MB-231 cells into the mammary fat pads of nude mice. MARK4 mRNA levels, but not those for NRAS and PI3KC2B, were increased in metastatic as compared to primary lesions in these animals (Figure 6F and Appendix Figure S13). Interestingly, we confirmed the opposite correlation for miR-515-5p with the levels of this miRNA being down-regulated in metastatic lesions (Figure 6F). These data reinforce the notion that MARK4 is the main miR-515-5p target regulating cell migration and metastasis. However, while these data suggested that the miR-515-5p/MARK4 axis may be regulated in the context of metastatic disease, it did not draw a direct link between miR-515-5p expression levels and the onset of metastasis. Hence, we performed an experiment to assess how overexpression of this miRNA would influence the ability of cancer cells to colonise SCID mice following tail vein injection. Contrary to cells transfected with a non-targeting control, miR-515-5p-overexpressing A549 cells failed to establish tumors in these animals (Figure 6G) demonstrating the direct ability of miR-515-5p to regulate the metastatic abilities of cancer cells. In addition, similarly to miR-515-5p overexpression, MARK4 silencing prevented lung colonisation by A549 cells (Figure 7A-B), showing that the reduction of invasive potential observed in vitro following MARK4 downregulation extends to the in vivo setting.

In summary, we demonstrate here that miR-515-5p over-expression inhibits cell migration by down-regulating MARK4 mRNA levels in both breast and lung cancer (Figure 7C), suggesting the importance of miR-515-5p/MARK4 mechanism across different cancer types. We showed that miR-515-5p and MARK4 levels are significantly down-regulated/ up-regulated in metastatic breast cancer tissues compared to primary tumor tissues, respectively, demonstrating the clinical relevance of our findings and indicating in the future that perhaps a miR-515-5p-based therapy as possible treatment to prevent the migration of cancer cells from the primary tumor. Finally, the correlation between miR-515-5p/MARK4 expression and the outcome of metastatic breast and lung
cancer suggests the use of miR-515-5p and MARK4 as prognostic molecular biomarkers for metastatic cancer patients. Also, as MARK4 specific inhibitors have now been developed [24], our data suggest that these molecules may be useful in the clinic to prevent metastatic dissemination of lung, breast and possibly other cancers.

**MATERIAL AND METHODS**

**Cell lines** The human MCF7, MDA-MB-231, MDA-157, A549 and H1299 were obtained from ATTC (Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle’s medium (Gibco) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C with 5% CO₂.

**Luciferase assay** MCF7 and MDA-MB-231 cells were plated in 24 well plates and were allowed to adhere and grow overnight at 37°C with 5% CO₂. The following day, the cells were co-transfected with pLightSwitch_3UTR GoClone vectors, and the indicated 50nM of miRNA precursors (pre-miRs mimics, Ambion) using lipofectamine™ 2000 (Invitrogen). The sequences for the 3'UTRs used were those for the following Gene IDs: PIK3C2B Gene ID: 5287; NRAS Gene ID: 4893; MARK4 Gene ID: 57787. After 24 h, cells were lysed using a passive lysis buffer (Promega, Southampton, UK) and processed with the LightSwitch Assay System (Switchgear Genomics Menlo Park CA, USA) according to manufacturer’s instructions. Luciferase activity detection was performed using a GLOMAX 96 Microplate luminometer (Promega).

**MicroRNAs, siRNAs and plasmids transfection** Cells were plated and allowed to adhere and grow overnight at 37°C with 5% CO₂. The following day, cells were transfected with 50 nM of pre-miRs (Ambion) or 30 nM of siRNAs (Dharmacon,
Appendix Table S1) using the HiPerFect transfection reagent (Qiagen) according to the manufacturer’s instructions. 24 h later, cells were transfected with control (pCDNA 3.0) or HA-MARK4 plasmid (kind gift from Dr Drewes [6]) using Attractene and according to the manufacture instructions.

**Immunofluorescence** Cells were fixed in 4% PFA at 37 °C for 15 min, washed in PBS and then blocked in 3% BSA at room temperature for 1 h. Actin cytoskeleton was stained with Alexa 488 Phalloidin (Invitrogen), microtubules with an anti-beta-tubulin antibody (Sigma) and nuclear DNA visualised using DAPI (Invitrogen) at 4ºC overnight. The following day, the stained cells were washed twice with PBS, secondary TRITC-antibody added for 1 hour, the cells washed thrice with PBS. Images were acquired using an ImageXpress High Content Screening microscope (Molecular Devices), 48 fields per condition.

**Cellular Circularity factor** Actin cytoskeleton staining of miR-515-5p and control miRVana transfected cells was performed using Alexa 488 Phalloidin as described above and fluorescent microscopy images for 10 fields per condition were acquired on an Image Xpress screening microscope (Molecular Devices). The cellular circularity factor was calculated for individual cells in Image J following the formula $4\pi A/P^2$, where $A$ is the cell area and $P$ the cell perimeter.

**Cell cycle analysis by FACS** The Click-iT® EdU cell proliferation assay kit (Life Technologies) was used to assess changes in cell cycle profile. Following the desired treatment, before harvesting the cells, 5-ethynyl-2'-deoxyuridine (EdU) was added to the culture medium (10 μM) for 1 h, at 37°C 10% CO₂, to allow for incorporation into the DNA during active DNA synthesis. Cells were then trypsinised, pelleted and washed with 1% (w/v) BSA in PBS. 100 μl of Click-iT® fixative was added and incubated at room temperature, in the dark, for 15 min. The cells were again washed with 1% BSA PBS.
and permeabilised with 100 μl of 1X Click-iT® saponin-based permeabilisation buffer/wash reagent for 15 min. As per the manufacturer’s instructions, 1X Click-iT® reaction cocktail was prepared (For 1ml; 100 μl 1X Click-iT® EdU buffer additive, 875 μl PBS, 20 μl CuSO4, 5 μl Alexa Fluor® 488 azide) and 500 μl added to the cells at room temperature for 30 min in the dark. Cells pellets were then washed with 1X Click-iT® saponin-based permeabilisation and wash reagent once before being re-suspended in 500 μl 1X Click-iT® saponin-based permeabilisation and wash reagent. The stained cells were analysed using the FACSDiva software v6.12 on a FACSCanto A flow cytometer. Data was analysed using FlowJo v7.6.5 (Tree Star Inc).

**Cell tracking assay** 1x10³ cells per well, were plated in black, flat and clear bottomed 96 well plates (BD Biosciences). Time-lapse imaging was performed for 18 h (1 image/10 min) using a motorized-staged environment-controlled ImageXpress high content screening microscope powered by MetaXpress 2.0 (Molecular Devices). Two sites were acquired per well, each condition was present in triplicate. To quantify the degree of migration a minimum of 30 cells per condition were tracked using MetaXpress Track Points application. Tracks were analyzed using a previously published using Mathematica (Wolfram Research) notebook [17].

**Boyden chamber assay** For transwell migration assays, 5 x 10⁴ cells were seeded at the top uncoated membranes with 8.0 μm pores (BD Biosciences). Cell were plated in serum free-medium and allowed to migrate toward a complete growth medium for 8 h. The cells on the bottom part of the filter were then stained using crystal violet. Stained cells were then imaged using Olympus BX51 microscope. Directional migration was quantified by cell counting using ImageJ [18].

**Microtubule comet imaging and analysis** To analyse the speed of microtubule growth a plasmid encoding GFP tagged End Binding Protein 3 (EB3) was used. The plasmid
was transfected into A549 cells 24 h before the cells were re-plated into 8-well chamber slides (PAA laboratories). During re-plating, cells were reverse transfected with siRNA against the MARK4 or a non-targeting control siRNA. Cells were then incubated for 24 h at 37°C 10% CO2. The movement of the EB3-GFP comets was imaged in individual cells using a Zeiss LSM-780 inverted microscope (Zeiss) using the Zen Black software (Zeiss) and a 40x magnification lens with one image acquired per sec for a total of 2 min on a 1.3 μm z-section. A total of 12 cells per condition were imaged in each independent repeat experiment. Comets were tracked using FIJI ImageJ (NIH, USA) and the plugin wrMTrck (J.Pedersen) to determine comets speed.

**RNA-Seq and ChIP-Seq analysis** Two micrograms of total RNA from each sample was used to produce cDNA libraries from polyA enriched RNA using the True-Seq RNA preparation kit (Illumina Inc.,San Diego, CA, USA) according to the manufacturer instructions. Paired end sequences (reads) 100 nt in length were then generated using a HiSeq 2000 instrument (Illumina). Fastq files containing the sequenced reads, obtained at the end of the sequencing, were mapped to the University of California at Santa Cruz (UCSC) human genome (hg19 assembly) with TopHat version 1.4.1 (http://tophat.cbcb.umd.edu), using default settings. The mapped bam files obtained at the end of the runs were then analyzed using Cufflinks version 2.1.0 (http://cufflinks.cbcb.umd.edu) for RNA quantification and analysis. The RNA-Seq raw data have been deposited in the ENA database with accession number PRJEB11884.

**MicroRNAs and mRNA expression** RNA was isolated using Trizol reagent according to the manufacture instructions. MicroRNA levels were quantified using TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems), TaqMan 2x Universal PCR Master Mix No AmpErase UNG (Applied Biosystems) and has-pre-miR-515-5p taqman primers (Applied Biosystems). To analyze mRNA expression, both cDNA conversion and qPCR amplification were performed as recommended by Applied Biosystems using the
High-Capacity cDNA Reverse Transcription Kit and Fast SYBR® Green Master Mix, respectively. The primers used for NRAS, PI3KC2B, FZD4, CDC42BPA, MARK4 and GAPDH are detailed in Appendix Table S2.

**Tumor tissues – microRNA expression** MicroRNA expression analysis in formalin-fixed paraffin embedded (FFPE) was approved by a UK national research ethics committee (London; 07/Q0401/20) and by Imperial College Healthcare NHS Trust. We prospectively measured miR-515-5p expression in primary BCs and corresponding lymph node metastasis from patients with lymph node positive BC. Between January 2008 and February 2010, we obtained primary breast tumours and corresponding lymph node metastases at Imperial College Healthcare NHS Trust, London, UK. All samples were formalin-fixed and paraffin-embedded. Clinico-pathological information about the patients is provided in Appendix Table S3.

**Lung cancer versus normal lung cDNA arrays** The levels for MARK4 mRNA were determined in the HLRT104 TissueScan cDNA array (Origene) containing 24 lung cancer and matching normal lung samples were analysed by using the Fast SYBR Green PCR Master Mix and 7900HT Real-time PCR System (Applied Biosystems). The housekeeping genes hypoxanthine phosphoribosyl-transferase (HPRT) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as reference genes to normalise the expression of target genes. Primers used are presented in Appendix Table S2. Analysis of relative gene expression was carried out using the qbasePLUS 2.1 software (Biogazelle).

**Immunohistochemistry** The lung cancer tissue microarray (TMA) BC041114 containing 90 cases of lung carcinoma and 10 normal tissue samples was purchased from Insight Biotechnology Limited (UK). For the syngenic primary tumor/metastasis tissue microarray, 100 lung cancer cases (Ethic Ref: 06/Q0406/154) were considered
suitable on the basis of histotype confirmation and immunostaining for pan-cytokeratin MNF116 and Vimentin. Tissue microarrays were prepared by obtaining three 1mm cores from the most representative and better preserved areas of the tumors and re-embedded in microarray blocks.

TMAs were stained using a primary antibody against MARK4 (Sigma-Aldrich, SAB1300394) used at a 1:50 dilution. A semi quantitative scoring of the histochemical staining was used as previously published by us [19]. The intensity of the staining was given a score of 0, negative, to 3, strongly positive. The percentage coverage of the staining was assessed and scored between 0 and 100%. Scores were multiplied together to give a range of possible scores between 0 and 300. The cores were all scored bind of all clinical data. The TMA data for each array was analysed separately then appropriately grouped to assess any changes in MARK4 protein levels in tissue within different stage, grade’s, classification of tumors.

Animal experiment A549 cells stably expressing luciferase (A549-Luc-C8, Xenogen) were transfected with 50nM pre-miR-515-5p or miRVANA control using Hiperfect (Qiagen) or with 20nM MARK4 or non-targeting siRNAs. 48h later, 1.10^6 cells were injected in the tail vein of SCID mice (8 animals per group) and mice subjected to whole-body imaging under anaesthesia, at 1 and 4 weeks, following tail-vein administration of luciferin or sacrificed at 4 weeks prior to their lungs being extracted, fixed in 70% ethanol, paraffin-embedded and stained for luciferase expression by immunohistochemistry (anti-luciferase antibody, sc-32896 from Santa Cruz Biochechnology). For the latter, images were acquired under microscopic observation and at x10 and x40 magnification. The percentage of field of view area covered by luciferase staining in 10x magnification images was quantified under FIJI-Image J. Animal experiments were carried out according to the National Guidelines for Experimental Animal Welfare (MOST, P.R.
China, 2006) in a SPF facility certified by the Hubei Provincial Office of Science and Technology (SYXKE 2009−0051).

**Statistical analysis** All data in the figures is presented as the mean ± standard error of mean (SEM) and assessed by using one way ANOVA analysis followed by a Tukey’s test (95% confidence) for multiple comparisons (SPSS version 17). P value of <0.05 is considered statistically significant.

**Figure legends**

**Figure 1. miR-515-5p expression changes the tubulin cytoskeleton and inhibits migration of breast and lung cancer cells.** (A) miR-515-5p expression increases the area of the tubulin cytoskeleton. Tubulin (green) and cell nucleus (blue). Objective x20. Bar: 200 µm. (B-C) miR-515-5p inhibits random (B) and directed (C) cell migration. The indicated cell lines were transfected with miR-515-5p for 48 h before time-lapse imaging was performed for 18 h (A) or transwell migration assays were performed for 9 h (C). (B-left panel) Plots show overlays of representative trajectories travelled. (B-right panel) The distance of migration was quantified and represented as the mean ± SEM of values normalised to the respective control condition. (C-left panel) Representative field of view from the bottom of the transwell chambers. Scale bar is 20 µm. (C-right panel) Data represent percentage of the average number migratory cells per field (n=5 fields per condition). Data are mean of three experiments ± SEM. (B-C) P values were calculated by t-test between miRNA (515-5p) values and their respective non-targeting control miR (NC) values (***, P<0.001). All data shown are representative of experiments performed at least in triplicate.

**Figure 2. miR-515-5p regulates mRNAs involved in cell migration.** (A) RNA-seq of MCF7 and MDA-MB-231 transfected with miR-515-5p revealed the down-regulation of
five transcripts, NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4. (B-D) The effect of miR-515-5p overexpression on NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 mRNA levels in MCF7 (B), MDA-MB-231(C), A549 and H1299 (D) was determined by qPCR 48 h following transfection of the indicated cell line with non-targeting control miR (NC) or miR-515-5p. Data is displayed as the normalised mean ± SEM. P values were calculated by t-test between miRNA conditions and their respective NC conditions (*, P<0.05; **, P<0.01; ***, P<0.001). (E-F) miR-515-5p directly interacts with NRAS, MARK4 and PI3KC2B’s 3’UTR. Relative luciferase activity levels were measured 24 h after co-transfection of MCF-7 (E) and MDA-MB-231 (F) with 3’UTR-luciferase reporter constructs and either with miR-515-5p or miR NC. Data shown are normalised mean of three independent experiments ± SEM. (B-F) P values were calculated by t-test between miRNA conditions and their respective NC conditions (*, P<0.05; **, P<0.01; ***, P<0.001).

**Figure 3. MARK4 knockdown mimics the effect of miR-515-5p overexpression.**

MARK4 siRNA-mediated silencing increases the tubulin cytoskeletal area (A) and reduces random (B) and directed (C) migration in MDA-MB-231 (MDA), A549 and H1299 cells. (A) Data shown are representative of experiments performed in triplicate. Bar graph represents the average ± SEM of n ≥ 50 per technical replicate with 3 technical replicates per conditions. Cells were transfected either with siRNA targeting MARK4 (M4) or a non-targeting control (NC) for 48 h before time-lapse imaging was performed for 18 h (B) or transwell assay for 9h (C). (B-top panel) Plots show overlays of representative trajectories described. (B-bottom panel) The migration distance was quantified and represented as the normalised mean ± SEM. (C-top panel) Representative field of view from the bottom side of the transwell membrane. (C-bottom panel) Graphs indicate cell migration expressed as a percentage of the average of migratory cells per field (n=5 fields per condition). (B-C) Data are mean of three
experiments ± SEM. (A-C) P values were calculated by t-test between the siRNA-transfected and the respective control condition (***P<0.001).

**Figure 4.** MARK4 over-expression rescues the inhibitory effects of miR-515-5p on cell migration. **(A-B)** The indicated cell lines were transfected with either miR515-5p or a non-targeting miR (miR NC) together with a MARK4 expressing or an empty vector (EV) plasmid DNA. MARK4 over-expression rescues the inhibition by miR-515-5p of random (A) and directed (B) migration of the indicated cell lines. (A-left panel) Plots show overlays of representative trajectories described for MDA-MB-231 cells (n=30). (A-right panel) The migration distance was quantified and represented as the normalised mean ± SEM. (B-left panel) Representative field of view from the bottom side of the transwell membrane for MDA-MB-231. (B-right panel) Graphs indicate cell migration expressed as a percentage of the average of migratory cells per field (n=5 fields per condition). Data are mean of three experiments ± SEM. (A-C) P values were calculated by t-test between the transfected and the respective control condition (EV+miR-NC) (*,P<0.05; **,P<0.01; ***,P<0.001).

**Figure 5.** MARK4 expression levels increase during tumorigenesis and correlate poor patient prognosis. **(A-B)** Overall survival of ER-negative metastatic breast cancer (n=226) (A) and lung adenocarcinoma (n=719) (B) patients according to MARK4 mRNA levels found in their tumors was represented using the Kaplan Meier-plotter [25]. (C) A cDNA array for 24 matched lung cancers and surrounding normal tissue was analysed for MARK4 expression. Expression levels from tumors were normalised to their respective normal control and the percentage of cases for the indicated fold expression in the tumor represented as a pie-chart. **(D-F)** MARK4 protein expression was determined by histoimmunochemistry in (D-E) a tissue microarray comprising 90 lung tumor and 10 normal lung samples or (F) a home-made tissue microarray comprising 100 matched cases of primary and metastatic tumors. **(D-E)** The
percentage of positivity for MARK4 staining in lung tumors versus normal lung samples (D) or in lung tumors according to their histological subtypes (E) is represented. (F) The percentage of cases with increased, decreased or unchanged levels of MARK4 in metastatic lesions as compared to the corresponding primary tumors is represented.

**Figure 6. miR-515-5p expression is inversely correlated with breast cancer metastasis and correlates with good patient prognosis.** (A-D) Low expression of miR-515-p is linked to survival in both Lung and Breast cancer. (A) Survival analysis of miR-515-5p from 195 lung adenocarcinoma samples from the TCGA. (B) Survival analysis of miR-515-p from 34 lung squamous cell carcinoma from the TCGA. (C) Survival analysis of miR-515-5p from 60 Breast cancer samples from the Lyng Ditzel Breast Study (GSE37405). (D) Survival analysis of miR-515-5p from 33 Breast cancer from the GSE7405 Breast study. Analysis and plot were obtained with SurvMicro http://bioinformatica.mty.itesm.mx:8080/Biomatec/Survmicro.jsp for (A-C) and with MIRUMIR for (D). (E) Comparison of miR-515-5p expression in 18 primary and matched metastatic lesions from breast cancer patients. miR-515-5p levels were quantified by TaqMan qRT-PCR. Absolute values were normalized to u6 snRNA values and displayed as a dot-plot. Bar; Mean, Whiskers; SEM. (F) MDA-MB-231 cells were inoculated into the mammary fat pads of nude mice and allowed to form metastatic deposits [22]. miR-515-5p and MARK4 levels were then determined in the primary and indicated secondary lesions. Data are average ± SEM of technical triplicates. (G) Luciferase-expressing A549 cells overexpressing miR-515-5p or a non-targeting control (miR-NC) were injected in the tail-vein of SCID mice and the development of tumor burden monitored by whole animal-imaging in response to luciferin administration at week 1 and 4 following injection. (G-left panel) Representative imaging of the same animals for the indicated conditions at week 1 and 4. (G-Right panel) The emitted photons were quantified and the signals normalised to the corresponding readings at week 1. Data represented are representative of three
independent experiments. (E-G) P values were calculated by t-test (*, P<0.05; **, P<0.01; ***, P<0.001).

Figure 7. miR-515-5p overexpression or siRNA-mediated MARK4 silencing prevents A549 cell metastasis to the lung. A549-Luc cells transfected either with miR-515-5p precursor (miR), siRNAs to MARK4 (siMARK4) or the corresponding control sequences (C and NT, respectively) were injected in Scid mice through the tail vein. 4 weeks later, the mice were sacrificed, their lungs extracted and fixed prior to staining for Luciferase expression. (A) Representative pictures showing the presence of A549-Luc cells in the lungs of NT mice either as single cells (upper panel) or as a tumour mass (lower panel). (B) Percentage of the area covered by tumour cells on randomly observed fields of views. Quantification was performed using Photoshop CS4. Each spot corresponds to quantification of an individual 1 mm x 1.5 mm field. Transversal bar; Median. Statistics: Student t-test. *, p≤0.05. (C) Schematic summary. Increase in MARK4 expression is the main reason for miR-515-5p-down-regulated cells to show increased metastatic abilities in breast and lung cancer. The down-regulation of miR-515-5p de-represses MARK4 translation in individual cells from the primary tumour promoting their metastatic dissemination through the blood or lymphatic circulation and reducing patients' survival.
REFERENCES

1. Kato T, Satoh S, Okabe H, Kitahara O, Ono K, Kihara C, Tanaka T, Tsunoda T, Yamaoka Y, Nakamura Y *et al.*: Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis. *Neoplasia* 2001, 3(1):4-9.

2. Beghini A, Magnani I, Roversi G, Piepoli T, Di Terlizzi S, Moroni RF, Pollo B, Fuhrman Conti AM, Cowell JK, Finocchiaro G *et al.*: The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is up-regulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. *Oncogene* 2003, 22(17):2581-2591.

3. Brajenovic M, Joberty G, Kuster B, Bouwmeester T, Drewes G: Comprehensive proteomic analysis of human Par protein complexes reveals an interconnected protein network. *J Biol Chem* 2004, 279(13):12804-12811.

4. Sontag JM, Nunbhakdi-Craig V, White CL, Halpain S, Sontag E: The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies. *J Biol Chem* 2012, 287(18):14984-14993.

5. Naz F, Anjum F, Islam A, Ahmad F, Hassan MI: Microtubule affinity-regulating kinase 4: structure, function, and regulation. *Cell Biochem Biophys* 2013, 67(2):485-499.

6. Trinczek B, Brajenovic M, Ebneth A, Drewes G: MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes. *J Biol Chem* 2004, 279(7):5915-5923.

7. Calin GA, Croce CM: MicroRNA signatures in human cancers. *Nat Rev Cancer* 2006, 6(11):857-866.
8. Osaki M, Takeshita F, Ochiya T: MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 2008, 13(7):658-670.

9. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D et al: Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via down-regulation of multiple cell-cycle genes. Mol Ther 2010, 18(1):181-187.

10. Higashijima A, Miura K, Mishima H, Kinoshita A, Jo O, Abe S, Hasegawa Y, Miura S, Yamasaki K, Yoshida A et al: Characterization of placenta-specific microRNAs in fetal growth restriction pregnancy. Prenat Diagn 2013, 33(3):214-222.

11. Pinho FG, Frampton AE, Nunes J, Krell J, Alshaker H, Jacob J, Pellegrino L, Roca-Alonso L, de Giorgio A, Harding V et al: Down-regulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. Cancer Res 2013, 73(19):5936-5948.

12. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O: FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010, 70(17):6735-6745.

13. Wilkinson S, Paterson HF, Marshall CJ: Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol 2005, 7(3):255-261.

14. Cain RJ, Ridley AJ: Phosphoinositide 3-kinases in cell migration. Biol Cell 2009, 101(1):13-29.

15. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J: Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002, 8(11):3468-3474.
16. Lara R, Mauri FA, Taylor H, Derua R, Shia A, Gray C, Nicols A, Shiner RJ, Schofield E, Bates PA et al: An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. *Oncogene* 2011, 30(32):3513-3521.

17. Katso RM, Pardo OE, Palamidessi A, Franz CM, Marinov M, De Laurentiis A, Downward J, Scita G, Ridley AJ, Waterfield MD et al: Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. *Molecular biology of the cell* 2006, 17(9):3729-3744.

18. Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 2012, 9(7):671-675.

19. Dhillon T, Mauri FA, Bellezza G, Cagini L, Barbareschi M, North BV, Seckl MJ: Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. *J Thorac Oncol* 2010, 5(3):314-319.

20. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A, Kandpal RP: Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. *Oncogene* 2006, 25(16):2328-2338.

21. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG: MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. *Cancer Res* 2009, 69(14):5776-5783.

22. Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H: NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. *J Biol Chem* 2003, 278(24):21631-21638.

23. Drewes G: Microtubule Affinity Regulating Kinases (MARK)- in *Encyclopedia of signaling molecules*. 2012.
24. Jenardhanan P, Mannu J, Mathur PP: The structural analysis of MARK4 and the exploration of specific inhibitors for the MARK family: a computational approach to obstruct the role of MARK4 in prostate cancer progression. *Mol Biosyst* 2014, 10(7):1845-1868.

25. Gyorffy B, Lánczky A, Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. *Endocr Relat Cancer* 2012, 19(2):197-208.

26. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. *Cancer Res* 2011, 71(17):5635-5645.
FIGURE 1

A

MCF7  |  MDA231  |  A549  |  H1299

miR NC

miR-515-5p

B

MDA231  |  A549  |  H1299

miR NC

miR-515-5p

Distance (%)

C

MDA231  |  A549  |  H1299

miR NC

miR-515-5p

Migratory cells (%)
All transcripts in miR-515-transfected MCF7 and MDA-MB-231

Significantly downregulated transcripts

miR-515-5p predicted direct targets

Role in cell migration

| Transcripts   | Role in migration                                                                 |
|---------------|-----------------------------------------------------------------------------------|
| N-RAS         | regulates actin cytoskeletal integrity and cell adhesion                           |
| FZD4          | induces EMT and loss of cell adhesion                                              |
| PI3KC2B       | implicated in the regulation of cell adhesion and actin reorganization             |
| CDC42BPA      | induces peripheral actin formation and promotes cytoskeletal reorganization        |
| MARK4         | involved in the reorganization of microtubules into bundles                        |

A

Transcripts Role in migration

B

MCF7

C

MDA-MB-231

D

A549

H1299

FIGURE 2
Figure 3

A: 

- MDA231
- A549
- H1299

siNC

siMARK4

B: 

- MDA
- A549
- H1299

Distance (µm)

C: 

- MDA
- A549
- H1299

Distance (%)

Migratory cells (%)
**FIGURE 4**

(A) MDA231

- miR NC/EV vs miR NC/pMARK4
- miR-515/EV vs miR-515/pMARK4

(B) MDA231

- miR NC/EV vs miR NC/pMARK4
- miR-515/EV vs miR-515/pMARK4

Distance (%)

** MD231  ** A549  H1299

| EV   | miR-NC | miR-515 | pMARK4 |
|------|--------|---------|--------|
| +    | +      | -       | +      |

Migratory cells (%)

** MD231  ** A549  H1299

| EV   | miR-NC | miR-515 | pMARK4 |
|------|--------|---------|--------|
| +    | +      | -       | +      |
FIGURE 5

**A**
MARK4 in ER-negative metastatic breast cancer

HR = 1.35 (0.91 – 1.98)
Logrank P = 0.13

**B**
MARK4 in adenocarcinoma

HR = 1.41 (1.21 – 1.65)
Logrank P = 7.2e-06

**C**

- Decrease: 8%
- 1-1.5 fold: 21%
- 1.5-2 fold: 37%
- 2-3 fold: 21%
- >3 fold: 13%

**D**

- Normal Tissue: 100%
- Primary Tumour: 63%

**E**

- Sq Cell Carcinoma: 34% (N=32)
- Adenocarcinoma: 53% (N=36)
- Other: 14% (N=22)

**F**

- No change: 31%
- Decreased: 41%
- Increased: 28%
Censored Survival Months

**A.** Lung adenocarcinoma

Concordance Index = 54.55, Log-Rank Equal Curves p = 0.0034, R² = 0.0366
Risk Groups Hazard Ratio = 1.77 (conf. int. 1.03 - 3.04), p = 0.0388

**B.** Lung squamous cell carcinoma

Concordance Index = 54.53, Log-Rank Equal Curves p = 0.0037, R² = 0.0369
Risk Groups Hazard Ratio = 1.76 (conf. int. 1.03 - 3.04), p = 0.0388

Censored Recurrence Months

**C.** Breast cancer (GSE37405)

Concordance Index = 54.78, Log-Rank Equal Curves p = 0.0032, R² = 0.0369
Risk Groups Hazard Ratio = 1.98 (conf. int. 0.99 - 4.13), p = 0.0684

**D.** Breast cancer (GSE7405)

Concordance Index = 54.53, Log-Rank Equal Curves p = 0.0037, R² = 0.0369
Risk Groups Hazard Ratio = 1.76 (conf. int. 1.03 - 3.04), p = 0.0388

Survival Analyses

Chisq 2.6 on 1 degrees of freedom, p = 0.108

**E.** Relative miR-515-5p levels (10⁻⁴)

Primary Metastasis

**F.** miR-515-5p (fold)

Primary tumour Lung Brain Adrenal glands

MARK4 mRNA (fold)

Primary tumour Lung Brain Adrenal glands

**G.** Tumour burden (fold)

Week 1 4

miR-NC miR-515

GSE7405 N Observed Expected (O-E)²/E (O-E)²/V

Group=high 12 2.58 4.84 1.056 2.59
Group=low 21 7.63 5.37 0.952 2.59

Group=1: low expression of hasa-mir-515-5p; Group=2: high expression of hasa-mir-515-5p

Survival Analyses

Chisq 2.6 on 1 degrees of freedom, p = 0.108

Breast cancer (GSE7405)

Metastasis

Primary Metastasis

Relative miR-515-5p levels (10⁻⁴)

0 1 2 3 4 5

0 1 2 3 4

Primary Metastasis

miR-NC miR-515

Tumour burden (fold)

Week 1 4

miR-NC miR-515

FIGURE 6
**FIGURE 7**

A. Micrographs showing changes in tumour area.

B. Bar graph showing the tumour area (% field) across different groups: NT, siMARK4, C, miR. * indicates statistical significance.

C. Diagram illustrating the role of MARK4 mRNA and miR-515-5p in promoting cell migration. Expanded tubulin cytoskeleton and change to tubulin cytoskeleton dynamics are also shown, along with the impact on metastasis and survival time.
APPENDIX

TABLE OF CONTENT

Tables and Figure legends PAGE 2
Appendix Table S1 PAGE 5
Appendix Table S2 PAGE 5
Appendix Table S3 PAGE 5
Appendix Figure S1 PAGE 7
Appendix Figure S2 PAGE 8
Appendix Figure S3 PAGE 9
Appendix Figure S4 PAGE 10
Appendix Figure S5 PAGE 11
Appendix Figure S6 PAGE 12
Appendix Figure S7 PAGE 13
Appendix Figure S8 PAGE 14
Appendix Figure S9 PAGE 15
Appendix Figure S10 PAGE 16
Appendix Figure S11 PAGE 17
Appendix Figure S12 PAGE 18
Appendix Figure S13 PAGE 19

APPENDIX TABLES AND FIGURE LEGENDS

Appendix Table S1. Sequence of MARK4 siRNAs (Dharmacon).

Appendix Table S2. Sequence of qRT–PCR primers.

Appendix Table S3. Clinico-pathological information of breast cancer patients.
Table EV1. Transcripts downregulated in MCF7 and MDA-MB-231 cells upon miR-515-5p overexpression.

Appendix figure S1: (A-B) The indicated cell lines were either transfected with a non-targeting control (NC) or a miR515-5p mimic and intracellular levels of miR515-5p determined 48h later by Taqman-based qPCR (A) or caspase 3/7 activity determined using a CaspaseGlo assay (B). (A) Data were normalized to u6 snRNA values and the mean of quadruplicates ± SEM. (B) Data are average of triplicate ± SEM of triplicate. (A-B) P values were calculated by t-test (***, P<0.001; n.s., non-statistically significant). Data shown are representative of experiments performed in triplicate.

Appendix figure S2: Overexpression of miR-515-5p leads to a loss of cell polarity. Breast (MDA 231 and MCF7) and lung (A549 and H1299) cancer cells were transfected with miR-515-5p mimics or control non-targeting miRVana prior to actin cytoskeleton staining and fluorescent microscopy image acquisition. The circularity factor was determined for individual cells and represented as a dot plot. Ten fields of view were analysed per condition. Horizontal bars: median value. Statistical analysis: ANOVA (***, P<0.001). Data shown are representative of experiments performed in triplicate.

Appendix figure S3: The effect of miR-515-5p sponges in NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 mRNA levels in MCF7 (A) and MDA-MB-231 (B). The miR-515-5p sponges were constructed by annealing, purifying and cloning oligonucleotides containing six tandem bulged miRNA binding motifs, into the HindIII and BamHI sites of the pEGFP-C1 plasmid (Contech, Saint-Germain-en-Laye, France). After 48 h of miR-515-5p sponges transfection, NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 mRNA levels were quantified by Syber Green qRT-PCR. Data were normalized to U6 snRNA values and are presented as the mean ± SEM of quadruplicates. P values were calculated by t-test comparing individual miR-515-5p sponges values with NC sponges values (***,P<0.001). Data shown are representative of experiments performed in triplicate.

Appendix figure S4: miR-515-5p expression in MCF7 and MDA-MB-231. miR-515 levels were quantified by Taqman qRT-PCR. Data were normalized to U6 snRNA values and are presented as the mean ± SEM of quadruplicates. Data shown are representative of experiments performed in triplicate.

Appendix figure S5: Luciferase reporter assay after co-transfection of MDA231 cells with hsa-miR-515-5p mimic and switchgear-3′UTR-MARK4 (Active Motif) reporter vector wild-type or mutated for the predicted sites A and B-miR-515-5p interaction sites. Bar graphs are the average ± SEM of triplicate. Data shown are representative of experiments performed in triplicate. The positions of the point mutations in the MARK4 UTR are shown above the bar graph and the corresponding sequences displayed underneath it. Data shown are representative of experiments performed in triplicate.

Appendix figure S6: (A) Efficient silencing of MARK4. The indicated cell lines were treated either with a MARK4 or a not targeting (NT) siRNA pool. Levels of MARK4 mRNA were determined 48h later by qPCR. Bar graphs are average of n=3 ± SEM normalised to the corresponding NT condition. (B-C) MDA157 cells were transfected with a MARK4, a not targeting (NT) siRNA pool, miR515-5p or a
corresponding non-targeting miR (NC). (B) Random cell migration assays were performed over 18 hour by live cell imaging and the distance covered by migrating cells determined by cell tracking. Data shown are average normalised measurements from n=30 cells per condition. (C) Cells were fixed and stained for nuclear DNA (DAPI, blue) and tubulin (green). Scale bar: 200µm. 27 fields per condition were acquired (×20) and the average tubulin area per cell calculated using Fiji and the fold changes ± SEM plotted. (B-C) Statistical analysis: ANOVA (**, P<0.01; ***, P<0.001). Data shown are representative of experiments performed at least in triplicate.

Appendix figure S7: (A) The indicated cell lines were transfected with either an empty vector (EV) or a MARK4 expressing plasmid DNA. MARK4 mRNA levels were determined 48h later. (B-C) The indicated cell lines were co-transfected with either miR515-5p or a corresponding non-targeting miR (NC) in the presence or absence of a MARK4 expressing (pMARK4) or an empty vector (EV) plasmid DNA and random cell migration (B) or transwell assays conducted. (A) Bar graphs show average of technical triplicate ± SEM. (B) Cell tracks of n=30 cells. (C) Crystal violet stained cells pictured on the bottom-side of the transwell filter. Results shown are representative of experiments performed in triplicate.

Appendix figure S8: MARK4 silencing leads to cell cycle arrest. A549 cells were transfected with MARK4 siRNA (Pool for (A) and (B) or individual targeting sequences 1 to 4 for (B)) or non-targeting sequences (NT). 48 hours later, the cells were fixed and stained with Click-it EdU prior to flow cytometric analysis (A) or the cell lysates subjected to SDS-PAGE/Western blotting for the indicated proteins. (A) The data were analysed in FlowJo for determining the proportion of cells in each phase of the cell cycle. Statistical analysis: ANOVA (*, P<0.05). Data shown are representative of at least three independent experiments (A and B) performed in triplicate (A).

Appendix figure S9: Change in tubulin polymerization speed. A549 expressing an EB3-GFP construct cells were transfected with MARK4 siRNA or non-targeting sequences (NT) and fast image acquisition performed using a Zeiss LSM-780 inverted confocal microscope using the Zen Black software (Zeiss). (A) Representative images of microtubule growth. (B) Quantification of the speed of microtubule growth. Comet speed was analysed using FIJI ImageJ (NIH, USA) and the plugin wrMTrck. Bar graphs are the average of triplicate experiments with n=12 cells per condition analysed in each experiment. Error bars indicate SEM. Asterisks represent statistically significant values from a minimum of three biological repeat experiments with three technical repeats (**, P<0.01; Students T Test).

Appendix figure S10: (A-B) Distant relapse-free survival of ER-negative metastatic breast (A) and overall survival of metastatic lung (B) cancer patients according to the levels of miR-515-5p. GEO2R analysis of miR-515-5p expression and survival using the dataset GSE22216 (ERα-negative lymph node-positive breast cancer patients, n=18) [26] and GSE16025 (lymph node-positive lung cancer patients, n=20) [21]. Survival values were divided in two cohorts by a Kaplan-Meier plot using GraphPad Prism: high miR-515-5p expression (> 8.20) and low miR-515-5p expression (< 8.20).

Appendix figure S11: Pearson correlation (r) was computed between the expression of miR-515-5p and MARK4 in various breast cancer subtypes from the TCGA breast cancer dataset.

Appendix figure S12: miR-515-5p expression of primary tumor and metastatic cells in breast cancer patients. RNA was isolated from 18 breast cancer tumor and metastatic tissues. miR-515-5p levels
were quantified by TaqMan qRT-PCR and analyzed either by comparing the paired values for each patient.

**Appendix figure S13**: NRAS and PI3KC2B expression of primary tumor and metastatic MDA-MB-231 cells in vivo. MDA-MB-231 cells were inoculated into the mammary fat pads of nude mice and allowed to form metastatic deposits. The levels of NRAS (A) and PI3KC2B (B) of both primary tumor and metastatic cells were then quantified by Syber Green qRT-PCR. Data were normalized to U6 snRNA values and are presented as the mean of triplicates ± SEM. P values were calculated by t-test comparing miR-515-5p values in metastasis with values in primary tumour (**, P<0.01). Results shown are representative of experiments performed in triplicate.
**Appendix Table S1.** Sequence of MARK4 siRNAs (Dharmacon).

| Supplier  | Target Gene | Dharmacon siGENOME siRNA ID | Sequence                  |
|-----------|-------------|-----------------------------|---------------------------|
| Dharmacon | MARK4       | D-005345-06                 | GCUGUACUCUCGAGCAAAAU      |
|           |             | D-005345-05                 | GGAUCAACAUCCGCUAUGA       |
|           |             | D-005345-02                 | GGAAGUACCGGGUCCUU        |
|           |             | D-005345-01                 | GAUCGAAGCGUGACACGUU      |

**Appendix Table S2.** Sequence of qRT–PCR primers.

| Target Gene | Forward primer sequence | Reverse primer sequence |
|-------------|-------------------------|-------------------------|
| NRAS        | TGTGATTTGCAAAAGGAC      | CAACACCCTGTCTGGTCTTT    |
| PI3KC2B     | TACCTCGTCCATCTCAAAGA    | GGAAGTCTCCATCAGCCAG     |
| FZD4        | CAACGTGACCAAGATGCC      | AGGAAGAACTGCAGCTGG      |
| CDC42BPA    | GTGATTTGGTCAGAGGAGCT    | ACATGCTGTCTCAGCTTTT     |
| MARK4       | GTCAACAGACTGTGAGAGCATCC | GCTCTGTGTAGGTCTTCACTCC  |
| GAPDH       | AGCCACATCGTCAGACAC      | GCCCAATACGACAAATCC      |
| HPRT        | TGACACTGGCAAAACATGCA    | GGTCCTTTCACCAGCAAGCT    |

**Appendix Table S3.** Clinico-pathological information of breast cancer patients.
| Patients | Sex | Age | Type of Ca | Grade | ER  | PgR | Her2 | EGFR |
|----------|-----|-----|------------|-------|-----|-----|------|------|
| 1        | F   | 50  | IDC        | 3     | -   | -   | 3+   | -    |
| 2        | F   | 94  | IDC        | 2     | -   | -   | -    | +    |
| 3        | F   | 33  | IDC        | 2     | -   | -   | -    | -    |
| 4        | F   | 57  | IDC        | 3     | -   | 1+  | 3+   | -    |
| 5        | F   | 68  | IDC        | 3     | -   | -   | -    | +    |
| 6        | F   | 59  | IDC        | 2     | -   | 1+  | -    | -    |
| 7        | F   | 52  | IDC        | 3     | -   | -   | -    | +    |
| 8        | F   | 45  | IDC        | 3     | -   | -   | 3+   | +    |
| 9        | F   | 57  | IDC        | 3     | -   | -   | 3+   | -    |
| 10       | F   | 79  | IDC        | 2     | -   | 1+  | -    | +    |
| 11       | F   | 70  | IDC        | 2     | -   | 1+  | -    | -    |
| 12       | F   | 44  | IDC        | 3     | -   | 1+  | 3+   | -    |
| 13       | F   | 39  | IDC        | 3     | 2+  | 2+  | -    | +    |
| 14       | F   | 44  | IDC        | 3     | 1+  | 1+  | 3+   | +    |
| 15       | F   | 40  | IDC        | 3     | 1+  | -   | -    | -    |
| 16       | F   | 64  | IDC        | 3     | 1+  | -   | -    | +    |
| 17       | F   | 47  | ILC        | 2     | 3+  | 3+  | -    | -    |
| 18       | M   | 62  | IDC        | 2     | 3+  | 2+  | 2+   | -    |
**APPENDIX FIG S1**

**A**

![Bar chart showing miR-515-5p/U6 levels across different cell lines.](image)

- A549
- H1299
- MDA-MB-231
- MCF7

**B**

![Bar chart showing Caspase 3/7 activity (fold) across different cell lines.](image)

- A549
- H1299

*** p < 0.001, n.s. not significant.
**APPENDIX FIG S5**

MARK4 3' UTR

miR-515-5p binding site A
Position 656-662

miR-515-5p binding site B
Position 1549-1555

---

| Site     | Luciferase activity (MDA-MB-231) |
|----------|----------------------------------|
| Site A mut | ![Bar chart](null)                |
| Site B mut | ![Bar chart](null)                |
| wild-type  | ![Bar chart](null)                |

---

5' GCUGAGGCCUAAAGACUGGAGAAU... MARK4 3' UTR A

wild-type

3' GUCUUUCAGAAAGAGAAACCUCUU miR-515-5p

---

5' GCUGAGGCCUAAAGAGUGCUCAA... MARK4 3' UTR A

mut

5' UGUGUUGGGAUGGAGAAU... MARK4 3' UTR B wild-type

3' GUCUUUCAGAAAGAGAACCUCUU miR-515-5p

---

5' UGUGUUGGGCAAUGGAGUCAA... MARK4 3' UTR B mut
APPENDIX FIG S6

A.

![Graph showing MARK4 mRNA (Fold) with siRNAs for various cell lines: H1299, A549, MAD231, MDA157, MCF7.]

B.

![Bar chart for MDA-157 showing distance (%).]

C.

![Images of cell cultures showing Sc, siMARK4, and 515-5p.](image)
**APPENDIX FIG S7**

**A**

![MARK4 overexpression](image)

**B**

![Cell distribution](image)

**C**

![Cell images](image)
APPENDIX FIG S8

A.

![Bar chart showing the percentage of cells in different cell cycle phases: G1, S, and G2/M.](chart)

- **G1**: NT, MARK4
- **S**: NT, MARK4
- **G2/M**: MARK4

B.

![Western blot results for p53, p21, and GAPDH.](blot)

- **siRNA**: NT, Pool 1, 2, 3, 4
- **MARK4**: Expressions of p53, p21, and GAPDH are shown.
APPENDIX FIG S9

**A**

siRNA

NT

MARK4

**B**

Comet Speed (Fold)

|       | siRNA | NT  | MARK4 |
|-------|-------|-----|-------|
| **0.0** | **1.0** | **1.4** | **1.2** |

**p**

**ER-negative metastatic breast cancer**

HR = 13.89 (3.415 - 46.48)  
logrank P = 0.0002

**miR-515 in metastatic lung cancer**

HR = 1.93 (0.69 - 5.38)  
logrank P = 0.2078

Relapse-free survival (%) vs Time (months) for ER-negative metastatic breast cancer and miR-515 in metastatic lung cancer.
APPENDIX FIG S11

Luminal A

\[ r = -0.05 \]
\[ P\text{value} = \text{n.s.} \]

Luminal B

\[ r = -0.35 \]
\[ P\text{value} = 0.03 \]

Basal

\[ r = -0.20 \]
\[ P\text{value} = \text{n.s.} \]

Normal

\[ r = -0.33 \]
\[ P\text{value} = 0.02 \]
